<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744977</url>
  </required_header>
  <id_info>
    <org_study_id>01642</org_study_id>
    <nct_id>NCT01744977</nct_id>
  </id_info>
  <brief_title>Cholesterol Medication Packaging Study</brief_title>
  <acronym>MWV_CAPS</acronym>
  <official_title>Evaluate the Efficacy, Perceptions and Cost of an Innovative Cholesterol Packaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durham VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durham VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the overall study is to improve medication use rates among veterans by looking
      at the risk factors of low-density lipoprotein cholesterol (LDL). It will involve patients
      who have high LDL-C level (&lt;130mg/dl) and /or may have difficulty taking their medications
      based on how often they refilled their medications in the last 12 months.

      The investigators will test an innovative adherence packaging relative to usual care. The
      primary hypothesis is that veterans who receive the intervention will have greater
      improvement in their medication adherence as measured by pill refill at 6 and 12 months of
      follow up as compared to the control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A sample of participants with elevated LDL level &gt;130 mg/dl and/or &lt;80% medication position
      ratio in the last 12 months (n=250) will be consented. The study sample will consist of both
      male and female subjects. Research assistants (RA's) will complete a baseline assessment and
      then randomly allocated participants to one of the following two groups:

        -  MeadWestvaco (MWV) Packaging Intervention. Patients randomized to the intervention group
           will receive the MWV medication adherence packaging and adherence education (Packaging
           Education.) at baseline from a research pharmacist. The participant will then receive
           their prescribed cholesterol medication in the MWV packaging over the next 12 months.

        -  The Education only Group - Patients randomized to the control group will receive
           educational material about LDL reduction at baseline.

      The study includes the following contacts with participants.

        -  Recruitment letter

        -  Telephone screening

        -  Baseline consent and interview - In person for all participants [Only Adherence
           Packaging Intervention participants will receive baseline discussion and education from
           the research pharmacist]

        -  6 month outcome assessment follow-up - In person for all participants

        -  12 month outcome assessment follow-up - In person for all participants

        -  12 month phone interview - Optional recorded qualitative interview for intervention
           participants only.

      All participants enrolled in study will be followed for 12 months.

      The study includes the following contacts with providers

      â€¢ Baseline consent and explanation of the adherence packaging - In person for all providers
      (group style visit)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol Medication Adherence</measure>
    <time_frame>12 months</time_frame>
    <description>Pill refill obtained at 12 months to review change in cholesterol medication adherence over the 12 month period between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol Level as Measured at Baseline, 6months, 12months</measure>
    <time_frame>Baseline, 6months, 12months</time_frame>
    <description>obtain non-fasting lipid panel at timepoints to review change in LDL cholesterol levels over the 12 month period (at baseline, 6 and 12 months)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Adherence Packaging Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Education Only Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed. The 6-month interval was selected to maintain contact with patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>packaging</intervention_name>
    <description>Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles</description>
    <arm_group_label>Adherence Packaging Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled in one of three Durham VA Medical Center (DVAMC) Primary Care clinics for at
             least one year

          -  AT least one visit to a primary care provider at the Raleigh Community Based
             Outpatient Clinic (CBOC) or DVAMC associated primary care clinics in the previous 12
             months

          -  Outpatient diagnostic code for hypercholesterolemia

          -  uncontrolled LDL in the last 12 months and/or poor LDL refill defined as &lt;80%
             medication adherence in the last 12 months

          -  prescribed whole tablets of simvastatin, rosuvastatin or pravastatin

        Exclusion Criteria:

          -  Diagnosis of metastatic cancer.

          -  Active diagnosis of dementia documented in medical record.

          -  Active diagnosis of psychosis documented in medical record with admission with last
             30days.

          -  Treated with dialysis

          -  Hospitalized for a stroke, myocardial infarction, coronary artery revascularization in
             past month.

          -  Severely impaired hearing, speech or sight. (Patients must be able to respond to phone
             calls and review adherence literature)

          -  Participating in another on-going cardio- vascular disease (CVD) risk management study
             (i.e., pharmaceutical trial or behavioral intervention)

          -  Does not have access to a telephone

          -  Resident in nursing facility that manages patients medications or

          -  Receiving home health care for extended period (home health service for limited time
             period will not exclude, i.e. scheduled surgical procedure not expected to require
             care for longer than 30 days)

          -  Planning to leave the area prior to the anticipated end of participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hayden B Bosworth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center/Durham VA Medical Center, Health Services and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VAMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Community-based Outpatient Clinic (CBOC- Raleigh)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2012</study_first_posted>
  <results_first_submitted>March 11, 2016</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2016</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adherence Packaging Intervention Group</title>
          <description>[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA (Research Assistant) on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
packaging: Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles</description>
        </group>
        <group group_id="P2">
          <title>Education Only Group</title>
          <description>Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Month Completed</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets inclusion</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adherence Packaging Intervention Group</title>
          <description>[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
packaging: Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles</description>
        </group>
        <group group_id="B2">
          <title>Education Only Group</title>
          <description>Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="8.9"/>
                    <measurement group_id="B2" value="62.9" spread="8.6"/>
                    <measurement group_id="B3" value="62.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American or Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cholesterol Medication Adherence</title>
        <description>Pill refill obtained at 12 months to review change in cholesterol medication adherence over the 12 month period between groups</description>
        <time_frame>12 months</time_frame>
        <population>Data on pill refill could not be obtained for 2 of the education only participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Adherence Packaging Intervention Group</title>
            <description>[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
packaging: Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles</description>
          </group>
          <group group_id="O2">
            <title>Education Only Group</title>
            <description>Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed.</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol Medication Adherence</title>
          <description>Pill refill obtained at 12 months to review change in cholesterol medication adherence over the 12 month period between groups</description>
          <population>Data on pill refill could not be obtained for 2 of the education only participants.</population>
          <units>adherence proportion</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".99" lower_limit="0.74" upper_limit="0.99"/>
                    <measurement group_id="O2" value=".94" lower_limit="0.60" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>With an assumed adherence proportion in the Control arm of 0.50, there is 80% power to detect a difference between Control and the intervention arms of 17% or more with 125 patients in each arm.</non_inferiority_desc>
            <p_value>0.300</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol Level as Measured at Baseline, 6months, 12months</title>
        <description>obtain non-fasting lipid panel at timepoints to review change in LDL cholesterol levels over the 12 month period (at baseline, 6 and 12 months)</description>
        <time_frame>Baseline, 6months, 12months</time_frame>
        <population>Cholesterol values could not be obtained for all patients at all time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Adherence Packaging Intervention Group</title>
            <description>[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
packaging: Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles</description>
          </group>
          <group group_id="O2">
            <title>Education Only Group</title>
            <description>Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol Level as Measured at Baseline, 6months, 12months</title>
          <description>obtain non-fasting lipid panel at timepoints to review change in LDL cholesterol levels over the 12 month period (at baseline, 6 and 12 months)</description>
          <population>Cholesterol values could not be obtained for all patients at all time points.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=120/119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.1" spread="38.8"/>
                    <measurement group_id="O2" value="111.6" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=112/115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.1" spread="29.4"/>
                    <measurement group_id="O2" value="105.8" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months (n=109/115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.3" spread="34.3"/>
                    <measurement group_id="O2" value="102.9" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>With an assumed adherence proportion in the Control arm of 0.50, there is 80% power to detect a difference between Control and the intervention arms of 17% or more with 125 patients in each arm.</non_inferiority_desc>
            <p_value>0.839</p_value>
            <p_value_desc>As measured at 12m</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
            <estimate_desc>This value summarizes the full 12 month period so Mean Difference (Final Values) is appropriate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 1 year study participation</time_frame>
      <desc>Patients were asked about adverse events at each follow-up appointment and a systematic review of the medical record was completed at each follow-up as well.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adherence Packaging Intervention Group</title>
          <description>[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
packaging: Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles</description>
        </group>
        <group group_id="E2">
          <title>Education Only Group</title>
          <description>Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Related Hospitalization or Visit</sub_title>
                <description>Includes: chest pain, MI, heart failure, hospitalization including surgery</description>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Obstruction- Hospitalization</sub_title>
                <description>Hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hospitalization-Gastrointestinal</sub_title>
                <description>Events include: small bowel obstruction and diverticulitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bee Sting- Emergency Room Visit</sub_title>
                <description>Bee sting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>General Hospitalization</sub_title>
                <description>chemotherapy complication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Death unrelated to study protocol</sub_title>
                <description>Unrelated pt deaths (cancer, CHF complications, not specified)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hospitalization-General</sub_title>
                <description>Events include: Re-occurring treatment for prior dx (spinal injury), Multi-factorial hospitalization causes, MVA events, &amp; Unspecified causes</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Scheduled Outpatient Surgery</sub_title>
                <description>Events include: laryngoscopy with lesion removal, thyroid nodule</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization-Infection</sub_title>
                <description>Sepsis related to kidney failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hospitalization-Infection</sub_title>
                <description>Events include: Fever during radiation treatment, Febrile Neutropenia, Cellulitis, Fainting, Food poisoning, UTI</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization-Musculoskeletal</sub_title>
                <description>Events include: Assault, Spinal surgery rehab, Fractures,</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Planned outpatient surgery- Shoulder</sub_title>
                <description>Rotator cuff repair</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hospitalization-Neoplasm</sub_title>
                <description>Events include: Lymphadenopathy sarcoma</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitaliztion- Nervous</sub_title>
                <description>Events include: spinal cord injury biopsy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations-Psychiatric</sub_title>
                <description>Events include: Psychiatric events (due to HIPAA can not collect/provide details)</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization-Renal</sub_title>
                <description>Increased Cr, acute renal failure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hospitalization- Renal</sub_title>
                <description>Events include: Renal failure, hematuria, Acute kidney disease</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Renal blockage- ER Visit</sub_title>
                <description>Events include: Blocked catheter,</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Scheduled Outpatient Surgery- Renal</sub_title>
                <description>Events include: PCN placement for ureteral obstruction, bladder tumor resection,</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding- Emergency Room Visit</sub_title>
                <description>Heavy bleeding accompanied by lightheadedness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization- Respiratory</sub_title>
                <description>Includes: pneumonia, lung disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hospitaliztion- Respiratory</sub_title>
                <description>Events include: Pneumonia, Lung Mass, Impaired gas exchange, pulmonary embolism</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Bronchitis/COPD- ER Visit</sub_title>
                <description>Pt came to ER for SOB via EMS.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Surgery</sub_title>
                <description>Knee Arthroplasty Surgery</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Surgery during Hospitaliztion</sub_title>
                <description>Event include:renal biopsy, amputation (and revision), coronary angiograph, lesion, lung removal, spinal cord bx, spinal surgery, carotid endarterectomy, tendon repair, tumor, nephrectomy, back surgery, hip arthroplasty, cath, appendix, etc</description>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization-Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hospitalization- Vascular</sub_title>
                <description>Events include: Stroke, Blood clot</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hayden Bosworth, PhD</name_or_title>
      <organization>Durham Veterans Affairs Medical Center</organization>
      <phone>919-286-6936</phone>
      <email>hayden.bosworth@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

